tbuckley/cabot-search huggingface dataset:
Paternal Depression Symptoms During Pregnancy and After Childbirth Among Participants in the Growing Up in New Zealand Study
Authors: Lisa Underwood, Karen E. Waldie, Elizabeth Peterson, Stephanie D’Souza, Marjolein Verbiest, Frances McDaid, Susan Morton
Journal: JAMA Psychiatry (2017)

<h3>Importance</h3> Antenatal and postnatal depression are known to be common and associated with poor outcomes for women and their children. There is little evidence on depression symptoms among men during the perinatal period. <h3>Objective</h3> To identify characteristics associated with depression symptoms among men whose partners were pregnant and subsequently gave birth. <h3>Design, Setting, and Participants</h3> A longitudinal cohort study provided data from a demographically diverse sample of 3523 New Zealand men who completed interviews during their partner's pregnancy and 9 months after the birth of their child. Participants were drawn from a cohort whose partners were pregnant women with a due date between April 25, 2009, and March 25, 2010, who were enrolled in the Growing Up in New Zealand study. Data analysis was conducted from September 1, 2015, to January 8, 2016. <h3>Main Outcomes and Measures</h3> Depression symptoms were measured using the Edinburgh Postnatal Depression Scale and the 9-item Patient Health Questionnaire; elevated depression symptoms were defined as scores higher than 12 and 9, respectively. <h3>Results</h3> The mean (SD) age of the participants at the antenatal interview was 33.20 (6.25) years (range, 16-63 years). Elevated antenatal paternal depression symptoms affected 82 fathers (2.3%) and were associated with perceived stress (odds ratio [OR], 1.38; 95% CI, 1.30-1.47) and fair to poor health during their partner's pregnancy (OR, 2.06; 95% CI, 1.18-3.61). Elevated postnatal paternal depression symptoms affected 153 (4.3%) of fathers and were associated with perceived stress in pregnancy (OR, 1.12; 95% CI, 1.08-1.17), no longer being in a relationship with the mother 9 months after childbirth (OR, 6.36; 95% CI, 2.28-17.78), having fair to poor health at 9 months (OR, 3.29; 95% CI, 2.10-5.16), being unemployed at 9 months (OR, 1.86; 95% CI, 1.11-3.10), and a history of depression (OR, 2.84; 95% CI, 1.69-4.78). <h3>Conclusions and Relevance</h3> Expectant fathers were at risk of depression symptoms if they felt stressed or were in poor health. Rates of elevated depression symptoms were higher during the postpartum period and were associated with adverse social and relationship factors. Identifying fathers most at risk of depressive symptoms and when best to target interventions (antenatal or postnatal) may be beneficial to men and their families.
Assessment of nivolumab (Nivo) benefit-risk profile from a 240-mg flat dose versus a 3-mg/kg dosing regimen in patients (Pts) with solid tumors
Authors: X. Zhao, S. Suryawanshi, M. Hruska, Y. Feng, X. Wang, J. Shen, B. McHenry, I.M. Waxman, A. Achanta, A. Bello, A. Roy, S. Agrawal
Journal: Annals of Oncology (2016)
Starting a multidisciplinary team for Adolescents and Young Adults with cancer in National Cancer Center Hospital
Authors: Seiko Bun, Makoto Kodaira, Asuka Kawachi, Atsuko Kitano, Saki Horiguchi, Mayumi Miyauchi, Chisato Kobayashi, Yoshio Oshima, Hiroyuki Terakado, Kenji Tamura
Journal: Annals of Oncology (2016)
Safety of Eribulin plus Trastuzumab in pre-treated HER2-positive advanced breast cancer (ABC) patients: results from an Italian observational study
Authors: L. Orlando, E.S. Lutrino, G. Giordano, C. Zamagni, C. Caliolo, A. Febbraro, M. Giampaglia, G. Dima, D. Rubino, C. Scavelli, P. Schiavone, D. Bilancia, G. Filippelli, A. Quaranta, P. Fedele, E. Mazzoni, C. Fontanella, S. Cinieri
Journal: Annals of Oncology (2016)
P06.14 Early biomarkers from conventional MRI and TRAMs for predicting response to bevacizumab in recurrent high-grade gliomas
Authors: D. Daniels, D. Guez, D. Last, A. Talianski, A. A. Kanner, D. T. Blumenthal, F. Bokstein, Z. R. Cohen, Y. Mardor, L. Zach
Journal: Neuro-Oncology (2016)

A subset of patients with recurrent high-grade gliomas benefits from the anti-angiogenic therapy bevacizumab (BVZ).An increased number of research efforts are performed to develop predictive biomarkers that allow for screening of patients.The immune system plays a crucial role in angiogenesis induction and maintenance.We analysed circulating immune cells in recurrent high-grade glioma patients treated with BVZ (10 mg/kg every 2 weeks) during a prospective bi-centric trial.Blood samples were collected before cycles 1, 3, 5 and 7 to perform flow cytometry analysis of monocytes (classical/intermediate/non-classical/ DRlow/ Tie2+/ VEGFR1+), Myeloid-Derived Suppressor Cells (MDSC) and regulatory T cells (Tregs) as well as a complete blood count.Thirty patients (29 Glioblastoma, 1 anaplastic astrocytoma) were enrolled between September 2012 and January 2014.Median OS and PFS were 9.1 months (6.7 -18.4; 95% CI) and 3.3 months (1.8 -5.1; 95% CI), respectively.During treatment results demonstrated a statistically significant increase in the median values of leukocytes, neutrophils, eosinophils, total and classical monocytes, as well as a statistically significant decrease of the percentage of Tregs among leucocytes.The strongest correlation between baseline levels of immune cells and OS were observed for neutrophils and Tregs.Patients with a percentage of Treg among leucocytes above the median (0.21 %) had an increased ] months, HR: 0.13 p<0.001).A lower baseline neutrophil count (< 3.8 G/L) was associated with a better OS (17.5 [12.2-n.a]versus 5.3 [5.3-10.1]months, HR: 0.27 p=0.002).Therefore, the detection of these cellular populations could provide insight into which patients may benefit from BVZ treatment.1P06.
Lenalidomide Has Activity in a Phase II Trial in Patients with Primary Systemic Amyloidosis.
Authors: Angela Dispenzieri, Martha Q. Lacy, Steven R. Zeldenrust, Susan M. Geyer, John A. Lust, Suzanne R. Hayman, Shaji K. Kumar, Jacob B. Allred, S. Vincent Rajkumar, Brian Kabat, Thomas E. Witzig, Philip R. Greipp, Steven R. Russell, Irene Ghobrial, Morie A. Gertz
Journal: Blood (2005)
Capecitabine and Regorafenib-related increased mean corpuscular volume of red blood cell may be a predictive marker of treatment response and survival in patients with metastatic colorectal cancer
Authors: M.A. Barbera, G. Frega, A. Palloni, F. Abbati, G. Biasco, I. Garajova
Journal: Annals of Oncology (2016)
Dose Dense, High Intensity Induction Therapy Followed by Early High Dose Chemotherapy (HDT) and Autologous Hematopoietic Stem Cell Transplantation(AHSCT) for Mantle Cell Lymphoma (MCL).
Authors: Liang-Piu Koh, Jon P. Gockerman, Joseph O. Moore, Carlos DeCastro, Gwynn D. Long, Cristina Gasparetto, Donna Niedzwiecki, Jon Edwards, Leonard Prosnitz, Mitchell Horwitz, Jon Chute, Ashley Morris, Martha Lassiter, Jennifer Loftis, Patty Davis, Nelson J. Chao, David A. Rizzieri
Journal: Blood (2004)
The<i>Galleria mellonella</i>larvae as an<i>in vivo</i>model for evaluation of<i>Shigella</i>virulence
Authors: Shoshana Barnoy, Hanan Gancz, Yuewei Zhu, Cary L. Honnold, Daniel V. Zurawski, Malabi M. Venkatesan
Journal: Gut Microbes (2017)

Shigella spp. causing bacterial diarrhea and dysentery are human enteroinvasive bacterial pathogens that are orally transmitted through contaminated food and water and cause bacillary dysentery. Although natural Shigella infections are restricted to humans and primates, several smaller animal models are used to analyze individual steps in pathogenesis. No animal model fully duplicates the human response and sustaining the models requires expensive animals, costly maintenance of animal facilities, veterinary services and approved animal protocols. This study proposes the development of the caterpillar larvae of Galleria mellonella as a simple, inexpensive, informative, and rapid in-vivo model for evaluating virulence and the interaction of Shigella with cells of the insect innate immunity. Virulent Shigella injected through the forelegs causes larvae death. The mortality rates were dependent on the Shigella strain, the infectious dose, and the presence of the virulence plasmid. Wild-type S. flexneri 2a, persisted and replicated within the larvae, resulting in haemocyte cell death, whereas plasmid-cured mutants were rapidly cleared. Histology of the infected larvae in conjunction with fluorescence, immunofluorescence, and transmission electron microscopy indicate that S. flexneri reside within a vacuole of the insect haemocytes that ultrastructurally resembles vacuoles described in studies with mouse and human macrophage cell lines. Some of these bacteria-laden vacuoles had double-membranes characteristic of autophagosomes. These results suggest that G. mellonella larvae can be used as an easy-to-use animal model to understand Shigella pathogenesis that requires none of the time and labor-consuming procedures typical of other systems.
C/EBPα and C/EBPα Myeloid Oncoproteins Inhibit Apoptosis and Induce Bcl-2 Via DNA-Binding Dependent and Independent Mechanisms.
Authors: Ido Paz-Priel, Dong Hong Cai, Dehua Wang, Caroline A. Heckman, Adrian F. Gombart, H. Phillip Koeffler, Linda M. Boxer, Alan D. Friedman
Journal: Blood (2004)
CT-guided fine-needle aspiration biopsy of pulmonary lesions under 15 mm of diameter: Results on 68 consecutive patients
Authors: D. Tosi, A. Palleschi, L. Rosso, P. Mendogni, I. Righi, R. Carrinola, F. Damarco, M. Cattaneo, L. Santambrogio
Journal: Annals of Oncology (2017)
Effective Treatment of Elderly Acute Myeloid Leukaemia (AML) with Continuous Combined Granulocyte Colony Stimulating Factor (G-CSF) and Single Oral Chemotherapeutic Agents.
Authors: Jennifer L. Curnow, Francesco Piccolo, Christopher M. Ward, Luke Coyle, Keith Fay, Naomi Mackinlay, Sundra Ramanathan, Christopher Arthur
Journal: Blood (2004)
Haploinsufficiency of Nf1 in Myeloid Lineages Contributes to Neurofibromatosis Type 1 Associated Skeletal Deficits
Authors: Steven D. Rhodes, Yongzheng He, Shi Chen, Hao Yang, Keshav M. Menon, Karl Staser, Xianlin Yang, Khalid S. Mohammad, Theresa Guise, Mingjiang Xu, Feng-chun Yang
Journal: Blood (2012)
Toward Optimised Intrapulmonary and Systhemic Hemostatic Interventions in Diffuse Alveolar Hemorrhage, a Single Center Experience
Authors: Miklos Udvardy, Anna Selmeczi, Miklos Egyed, Attila Szucs, Arpad Illes, Lajos Gergely, Joseph Balla, Janos Matyus
Journal: Blood (2015)
CD47 Monoclonal Antibody SRF231 Is a Potent Inducer of Macrophage-Mediated Tumor Cell Phagocytosis and Reduces Tumor Burden in Murine Models of Hematologic Malignancies
Authors: Pamela M Holland, Emmanuel Normant, Ammar Adam, Caroline M Armet, Rachel W O'Connor, Andrew C Lake, Jonathan A Hill, Detlev M Biniskiewicz, Scott C Chappel, Vito J Palombella, Alison M Paterson
Journal: Blood (2016)
Dose-Dense(dd) ABVD and Dose-Dense/Dose-Intense(dd-di) ABVD in Newly Diagnosed Patients (pts), Intermediate- and Advanced-Stage with Classical Hodgkin's Lymphoma (cHL): Final Results.
Authors: Filippo Russo, Gaetano Corazzelli, Secondo Lastoria, Gianpaolo Marcacci, Ferdinando Frigeri, Gaetana Capobianco, Cristina Becchimanzi, Manuela Arcamone, Antonio Pinto
Journal: Blood (2009)
Vaccinations Efficacy in Long Term Survivors After Allogeneic Stem Cell Transplantation: Implication of Repeat Vaccinations and Documenting Vaccination Efficacy.
Authors: Carey Clifton, Leigh Ann Vaughan, Catherine Lucid, Sharon Sims, Brian Engelhardt, Wichai Chinratanalab, Adetola A. Kassim, Stacey Goodman, John P. Greer, Friedrich Schuening, Madan Jagasia, Bipin N. Savani
Journal: Blood (2009)
Nomogram-based prediction of overall survival (OS) of patients (pts) with metastatic urothelial carcinoma (UC) receiving first-line platinum-based chemotherapy: retrospective international study of invasive/advanced cancer of the urothelium (RISC)
Authors: A. Necchi, G. Sonpavde, S.L.o. Vullo, A. Bamias, S.J. Crabb, L. Harshman, J. Bellmunt, U. De Giorgi, C. Sternberg, S. Ladoire, Y.-N. Wong, E.Y. Yu, S. Chowdhury, G. Niegisch, S. Srinivas, U. Vaishampayan, S.K. Pal, J. Rosenberg, L. Mariani, M.D. Galsky
Journal: Annals of Oncology (2016)
Inflammatory Niche Signalling Drives Genotoxic Stress in Hematopoietic Stem Cells and Predicts Leukemic Evolution in Human Leukemia Predisposition Syndromes
Authors: Si Chen, Noemi A. Zambetti, Zhen Ping, Keane Kenswil, Maria Mylona, Mathijs A. Sanders, Remco Hoogenboezem, Eric Bindels, Maria Adisty, Paulina M. H. van Strien, Cindy van der Leije, Theresia M Westers, Eline MP Cremers, Chiara Milanese, Pier Mastroberardino, Johannes van Leeuwen, Bram Van der Eerden, Ivo Touw, Kuijpers Taco, Roland Kanaar, Arjan van der Loosdrecht, Thomas Vogl, Marc H.G.P. Raaijmakers
Journal: Blood (2016)
Galactosylation of IgA1 Is Associated with Common Variation in C1GALT1
Authors: Daniel P. Gale, Karen Molyneux, David Wimbury, Patricia Higgins, Adam P. Levine, Ben Caplin, Anna Ferlin, Peiran Yin, Christopher P. Nelson, Horia Stanescu, Nilesh J. Samani, Robert Kleta, Xueqing Yu, Jonathan Barratt
Journal: Journal of the American Society of Nephrology (2017)

IgA nephropathy (IgAN), an important cause of kidney failure, is characterized by glomerular IgA deposition and is associated with changes in O -glycosylation of the IgA1 molecule. Here, we sought to identify genetic factors contributing to levels of galactose-deficient IgA1 (Gd-IgA1) in white and Chinese populations. Gd-IgA1 levels were elevated in IgAN patients compared with ethnically matched healthy subjects and correlated with evidence of disease progression. White patients with IgAN exhibited significantly higher Gd-IgA1 levels than did Chinese patients. Among individuals without IgAN, Gd-IgA1 levels did not correlate with kidney function. Gd-IgA1 level heritability (h 2 ), estimated by comparing midparental and offspring Gd-IgA1 levels, was 0.39. Genome-wide association analysis by linear regression identified alleles at a single locus spanning the C1GALT1 gene that strongly associated with Gd-IgA1 level ( β =0.26; P =2.35×10 −9 ). This association was replicated in a genome-wide association study of separate cohorts comprising 308 patients with membranous GN from the UK ( P &lt;1.00×10 −6 ) and 622 controls with normal kidney function from the UK ( P &lt;1.00×10 −10 ), and in a candidate gene study of 704 Chinese patients with IgAN ( P &lt;1.00×10 −5 ). The same extended haplotype associated with elevated Gd-IgA1 levels in all cohorts studied. C1GALT1 encodes a galactosyltransferase enzyme that is important in O -galactosylation of glycoproteins. These findings demonstrate that common variation at C1GALT1 influences Gd-IgA1 level in the population, which independently associates with risk of progressive IgAN, and that the pathogenic importance of changes in IgA1 O -glycosylation may vary between white and Chinese patients with IgAN.
Evolution of Cancer Stem-like Cells in Endocrine-Resistant Metastatic Breast Cancers Is Mediated by Stromal Microvesicles
Authors: Pasquale Sansone, Marjan Berishaj, Vinagolu K. Rajasekhar, Claudio Ceccarelli, Qing Chang, Antonio Strillacci, Claudia Savini, Lauren Shapiro, Robert L. Bowman, Chiara Mastroleo, Sabrina De Carolis, Laura Daly, Alberto Benito-Martin, Fabiana Perna, Nicola Fabbri, John H. Healey, Enzo Spisni, Monica Cricca, David Lyden, Massimiliano Bonafé, Jacqueline Bromberg
Journal: Cancer Research (2017)

The hypothesis that microvesicle-mediated miRNA transfer converts noncancer stem cells into cancer stem cells (CSC) leading to therapy resistance remains poorly investigated. Here we provide direct evidence supporting this hypothesis, by demonstrating how microvesicles derived from cancer-associated fibroblasts (CAF) transfer miR-221 to promote hormonal therapy resistance (HTR) in models of luminal breast cancer. We determined that CAF-derived microvesicles horizontally transferred miR-221 to tumor cells and, in combination with hormone therapy, activated an ER
GENT-12. MOLECULAR GROUPING OF TUMORS FROM PATIENTS WITH FAMILIAL GLIOMA
Authors: Vanessa Ruiz, Georgina Armstrong, Corinne Praska, Thomas Kollmeyer, Seiji Yamada, Paul Decker, Matthew Kosel, Jeanette Eckel-Passow, Daniel Lachance, Matthew Bainbridge, Beatrice Melin, Melissa Bondy, Robert Jenkins
Journal: Neuro-Oncology (2016)

Gliomas can segregate within families. Single gene mutations account for some of these families; such as those that occur in Li-Fraumeni, Turcot, and Familial Glioblastoma/Melanoma syndromes, as well as the recently described families with POT1 mutations. However, these mutations likely do not account for all familial risk. We have recently defined a method of classifying glioma into 5 groups based on three molecular alterations. We hypothesize that 1) if there is additional genetic risk in families, the gliomas in affected family members should be of similar molecular group, and 2) there may be variation in the prevalence of some molecular groups compared to the population at large. We studied probands and families from the GLIOGENE Familial Glioma Registry to address these questions. Peripheral blood for germline study and glioma tissue from probands in 76 families, including 10 families with one additional affected family member, were analyzed. Subjects were sequenced for germline mutations in TP53, POT1, CHEK1, BRCA1 and BRCA2, and their formalin-fixed, paraffin-embedded tumor DNA was analyzed using a first-generation Affymetrix molecular inversion probe (MIP) array. Array data permitted classification of tumors from 63 families. Prevalence of the molecular groups was: 31 TERT mutant only, 21 IDH1/2 mutant only, and 11 triple-positive (1p/19q co-deletion, TERT mutation, and IDH1/2 mutation). This distribution is not statistically different from that of sporadic gliomas (p=0.51). Of the 10 paired familial gliomas, 7 were concordant based on molecular group: three families segregated IDH mutant only, two TERT mutant only, and two triple-positive gliomas. Our data suggest that within individual families, patients develop gliomas in the same molecular group. We also observed that the prevalence of the molecular groups in familial glioma is similar to sporadic glioma. These observations have important implications for a possible mechanism of the genetic predisposition to glioma.
Unexpected Evidence That Inducible Nitric Oxide Synthase (iNOS) Is a Negative Regulator of Hematopoietic Stem/Progenitor Cell Mobilization
Authors: Mateusz Adamiak, Ahmed Abdelbaset-Ismail, Marcin Wysoczynski, Ahmed Abdel-Latif, Joseph B Moore, Janina Ratajczak, Mariusz Z Ratajczak
Journal: Blood (2016)
Long-term survivors (LTS) in glioblastoma (GBM) patients (pts) homogeneously treated with the Stupp regimen, clinical and molecular characteristics (MGMT and IDH1 status). Initial results from the GLIOCAT study
Authors: E. Pineda, M. Martinez-Garcia, A. Estival, M. Gil-Gil, S. Del Barco, O. Gallego, E. Verger, J. Marruecos, R. Fuentes, J. Craven-BartleLamote de Grigno, C. Mesía, N. García, F. Alameda, J.M. Velarde, T. Pujol, L. Oleaga, C. Carrato, J. Capellades, S. Villà, C. Balana
Journal: Annals of Oncology (2016)
PDTB-03. ROLE OF SMARCB1 IN PEDIATRIC RHABDOID TUMORS
Authors: Alison Parisian, Tomoyuki Koga, Robert Wechsler-Reya, Frank Furnari
Journal: Neuro-Oncology (2016)

Malignant rhabdoid tumors are challenging pediatric cancers which occur primarily in the brain and kidney and are predominantly associated with inactivation of the gene SMARCB1. As SMARCB1 is a conserved subunit of the chromatin remodeling BAF complex, we hypothesize that the effect of its loss of function is influenced by the epigenetic landscape of the cell in which deletion occurs, resulting in constrained age of onset and tissue specificity of tumor formation. To address this question, we generated a cell-based model of brain and kidney rhabdoid tumors using an inducible SMARCB1 loss of function system in human induced pluripotent stem cells (iPSCs). With this model, we are investigating the location-based effect of SMARCB1 deletion on the molecular pathways involved in brain and kidney tumorigenesis, with a guiding emphasis on the importance of cell type and stage of differentiation in the growth of these tumors. Specifically, the impact of SMARCB1 deletion on cell growth in vitro and in vivo will be quantified. Following the generation of SMARCB1-deleted orthotopic tumors, we will perform a global transcriptome analysis to identify changes in molecular pathways which may contribute to tumorigenesis. Ultimately, this model will be used to identify novel, therapeutically actionable targets which contribute to the phenotype of these tumors and to further understand the relationship between altered chromatin structure and oncogenicity.
A prospective analysis of quality of life (QoL), cognitive functions (CF) and psychological status (PSY) in glioblastoma (GBM) patients (PTS) treated with RT and Temozolomide (TMZ)
Authors: E. Bergo, E. Bergo, G. Lombardi, P. Del Bianco, F. Berti, L. Bellu, A. Pambuku, V. Zagonel
Journal: Annals of Oncology (2016)
Improved Outcome of Reduced Toxicity Fludarabine, Cyclophosphamide Plus Thymoglobulin Conditioning Regimen for Unrelated Donor Transplantation in Severe Aplastic Anemia: Comparison of Two Multicenter Prospective Studies
Authors: Hyoung Jin Kang, Ji Won Lee, Hyery Kim, Kyung Duk Park, Hee Young Shin, Hyun Joo Jung, Jun Eun Park, Jae Wook Lee, Nak Gyun Chung, Bin Cho, Hack Ki Kim, Jae Hee Lee, Yeon Jung Lim, Sun Young Kim, Eun Sun Yoo, Kyung Ha Ryu, Young Ho Lee, Jeong A Park, Young Tak Lim, Soo Hyun Lee, Keon Hee Yoo, Ki Woong Sung, Hong Hoe Koo, Kyung Nam Koh, Ho Joon Im, Jong Jin Seo, Sang Kyu Park, Hyo Seop Ahn
Journal: Blood (2012)
Mitochondria Coordinate Intracellular Metabolism and Epigenetic Gene Regulation during Erythropoiesis
Authors: Xin Liu, Yuannyu Zhang, Min Ni, Hui Cao, Robert Signer, Dan Li, Zhimin Gu, Zeping Hu, Navdeep Chandel, Ralph DeBerardinis, Feng Zhou, Zhen Shao, Jian Xu
Journal: Blood (2016)
EXTH-28. 5-AMINOLEVULINIC ACID-BASED PHOTODYNAMIC THERAPY OF GLIOBLASTOMA TUMORSPHERE AND ACQUIRED RESISTANCE BY TUMOR MESENCHYMAL STEM-LIKE CELLS
Authors: Junseong Park, Seung Jae Oh, Jin-Kyong Shim, Tae-Hoon Roh, Young Bin Ji, Kyoung Su Sung, Ju Hyung Moon, Eui Hyun Kim, Sun Ho Kim, Jong Hee Chang, Seok-Gu Kang
Journal: Neuro-Oncology (2016)

Despite first being used over 35 years ago, photodynamic therapy (PDT) and the related techniques of fluorescence guided resection and photodynamic diagnosis (PDD) have not been progressed as a standard of care. Here, we suggest clinical availability of PDD and PDT in glioblastoma using 5-aminolevulinic acid (5-ALA), which metabolized into the active fluorescent molecule protoporphyrin IX (PpIX). Treatment of 1mM 5-ALA showed distinct PpIX fluorescence in patient-derived glioblastoma tumorspheres (TSs), unlike normal human astrocytes, bone marrow mesenchymal stem cells, and tumor mesenchymal stem-like cells (tMSLCs). These results were negatively correlated with the expression levels of FECH, which is known to catalyzes the conversion of accumulated PpIX to heme. We also investigated the effects of PDT to 5-ALA-treated TSs using 12mW/cm2 laser at 635nm wavelength. 5-ALA-treated glioblastoma TSs were sensitive to PDT, showing significant decrease in cell viability and stemness. It was consistent whether TSs have sphere form or single cell form, even though sphere form required more energy (~10J/cm2). Notably, the effects of PDT were abolished when TSs were cultured with tMSLC-cultured media. We propose that the presence of tMSLC can be a plausible mechanism of PDT resistance in glioblastoma.
Local treatment with electrochemotherapy of superficial angiosarcomas: Efficacy and safety results from a multi-institutional retrospective study
Authors: M. Guida, L. Campana, P. Curatolo, S. Strippoli, A. Bonadies, G. Grilz, C. Cabula, R. Rotunno, S. Bucher, N. Solari, A. Santoriello, S. Valpione, C. Rossi
Journal: Annals of Oncology (2016)
NANOG expression as a responsive biomarker during treatment with Hedgehog signal inhibitor in acute myeloid leukemia
Authors: Seiji Kakiuchi, Yosuke Minami, Nobuaki Fukushima, Yu Mizutani, Keiji Kurata, Shinichiro Kawamoto, Kimikazu Yakushijin, Tomoki Naoe, Hiroshi Matsuoka, Hironobu Minami
Journal: Annals of Oncology (2016)